

## HOW TO DESIGN NUTRITIONAL INTERVENTION TRIALS TO SLOW COGNITIVE DECLINE IN APPARENTLY HEALTHY POPULATIONS AND APPLY FOR EFFICACY CLAIMS: A STATEMENT FROM THE INTERNATIONAL ACADEMY ON NUTRITION AND AGING TASK FORCE

M. FERRY<sup>1</sup>, N. COLEY<sup>2,3</sup>, S. ANDRIEU<sup>2,3,4,5</sup>, C. BONHOMME<sup>6</sup>, J.P. CAUBERE<sup>7</sup>, M. CESARI<sup>2,3,4</sup>, J. GAUTRY<sup>8</sup>, I. GARCIA SANCHEZ<sup>9</sup>, L. HUGONOT<sup>10</sup>, L. MANSUY<sup>7</sup>, M. PAHOR<sup>11</sup>, J. PARIENTE<sup>12</sup>, P. RITZ<sup>13</sup>, A. SALVA<sup>14</sup>, J. SIJZEN<sup>15</sup>, R. WIEGERS<sup>15</sup>, P. YTHIER-MOURY<sup>16</sup>, M. ZAIM<sup>17</sup>, J. ZETLAOUI<sup>18</sup>, B. VELLAS<sup>2,3,4</sup>

1. Nutritional Epidemiology Unit, U557 INSERM/U1125 Inra/Cnam/University Paris 13; 2. INSERM U1027, Toulouse, France; 3. University of Toulouse III, 31073 Toulouse, France; 4. Gérontopôle, Toulouse University Hospital, Toulouse, France; 5. Department of Epidemiology and Public Health, Toulouse, France; 6. Lactalis Nutrition Santé, 35370 Torcé, France; 7. Pierre Fabre, 81106 Castres, France; 8. Nestlé Clinical Nutrition, 77446 Marne la Vallée, France; 9. DG Sanco, Brussels, Belgium; 10. MedForma, Paris, France; 11. University of Florida, Gainesville, FL, USA; 12. Department of Neurology, Purpan Hospital, 31000 Toulouse, France; 13. Nutrition Unit, Toulouse University Hospital, Toulouse, France; 14. Institut Català de l'Envel·liment, Universitat Autònoma de Barcelona, Spain; 15. Nutricia Advanced Medical Nutrition, Danone Research, Centre for Specialized Nutrition, 6700 CA Wageningen, The Netherlands; 16. Sanofi R&D – TSU Aging, 34184 Montpellier, France; 17. Institut de Recherche Pierre Fabre, 31035 Toulouse, France; 18. Nestlé Health Science SA, 1800 Vevey, Switzerland. Corresponding author: M. Ferry, Nutritional Epidemiology Unit, Human Nutrition Research Center of Ile de France, UFR SMBH Paris 13, 75 rue Marcel Cachin, F-93017 Bobigny cedex, France. E-mail : monique.ferry@club-internet.fr

**Abstract:** Interventions are crucial as they offer simple and inexpensive public health solutions that will be useful over the long term use. A Task Force on designing trials of nutritional interventions to slow cognitive decline in older adults was held in Toulouse in September 2012. The aim of the Task Force was to bring together leading experts from academia, the food industry and regulatory agencies to determine the best trial designs that would enable us to reach our goal of maintaining or improving cognitive function in apparently healthy aging people. An associated challenge for this Task Force was to determine the type of trials required by the Public Food Agencies for assessing the impact of nutritional compounds in comparison to well established requirements for drug trials. Although the required quality of the study design, rationale and statistical analysis remains the same, the studies designed to show reduction of cognitive decline require a long duration and the objectives of this task force was to determine best design for these trials. Two specific needs were identified to support trials of nutritional interventions: 1- Risk- reduction strategies are needed to tackle the growing burden of cognitive decline that may lead to dementia, 2- Innovative study designs are needed to improve the quality of these studies.

**Key words:** Cognitive decline, aging, design nutritional intervention trials, efficacy claims.

### Introduction

Diet and nutrition are important factors in the promotion and maintenance of good health throughout the entire life course. Their role as determinants of chronic disease is well established and they therefore occupy a prominent position in global disease prevention activities (1). Alzheimer's disease (AD) and other dementias are among the most burdensome age-related chronic diseases. Thus, risk management strategies are urgently needed to tackle the growing burden of cognitive decline in the elderly.

Nutritional status has been implicated as one of the many potential risk factors for cognitive decline in elderly people. Nutritional interventions are of interest because they are usually safe, relatively inexpensive in comparison to pharmacologic intervention, and provide some unique opportunities for long-term use. A Task Force on designing trials of nutritional intervention for cognitive decline in older adults was held in Toulouse in September 2012. The aim of the Task Force was to bring together a limited number of leading experts from academia, the food industry, and regulatory agencies to determine the best trial designs for identifying nutritional

interventions that would enable us to reach our goal of maintaining or improving cognitive function with aging. Like trials of pharmacologic interventions, nutritional studies require clarity of rationale, appropriately selected trial designs, and rigorously applied statistical analysis. However, different types of data may be required to establish the impact of foods or supplements on cognition. The objective of this report is to provide an overview of the current landscape in the field and provide a summary of the discussion and outcomes of the meeting. Ultimately, the Task Force hopes to establish specific recommendations that will expedite the development of nutritional interventions in the elderly population.

### The role of food in maintaining or improving cognitive functions with age

AD is the most frequent cause of dementia in older persons. The main risk factors for late-onset AD (i.e., age and the presence of the ApoEε4 allele) are not modifiable. The identification of nutritional factors associated with increased risk of cognitive decline may consequently represent an opportunity to develop novel risk reduction strategies. Several





### A STATEMENT FROM THE INTERNATIONAL ACADEMY ON NUTRITION AND AGING TASK FORCE

epidemiological studies (2-4) and clinical trials (5-7)) have reported strong links between nutritional status and cognitive health in older persons, suggesting that specific nutrients may play a role of lowering the risk of cognitive decline, especially in frail elderly people at risk of nutritional deficiencies and incident AD. These studies were initially focused on specific deficiencies of micronutrients involved in neuroprotection and/or regulation of the oxidative status (8-15). For example, the protective effect of fish oil consumption has been attributed to its high content of long-chain omega-3 polyunsaturated fatty acids (PUFA), in particular docosahexaenoic acid (DHA) (16). Longitudinal and cohort studies also show an association between diabetes, hyperhomocysteinemia, hypercholesterolemia, low intake of n-3 fatty acids and oxidative stress with the risk of dementia. Nevertheless, evidence is still controversial, with epidemiologic studies failing to demonstrate a relationship between omega-3 PUFA intake and risk of dementia or cognitive decline. The most consistent evidence is available for longer-chain omega-3 fatty acids (often measured as fish consumption), with several longitudinal studies showing an association with reduced risk for cognitive decline (17). Another example might be provided by results from the Three-City (3C) study, which analyzed the relationship between fat- or antioxidant-rich dietary components and the risk of dementia in older persons. Authors found that the frequent consumption of fruits, vegetables, fish, and omega-3 rich oils may play a role at decreasing the risk of dementia, especially in ApoEε4-non carriers (2).

Large clinical trials have also been conducted to test the effects of nutritional supplements on the progression of cognitive decline. For example, a multicenter, randomized, double-blind placebo controlled clinical trial of antioxidants (600 mg vitamin E, 250 mg vitamin C and 20 mg β-carotene daily) failed to show any slowing of cognitive decline in the treatment group (18). Another multi-center trial of Docosahexaenoic acid (DHA) supplementation in individuals with mild to moderate AD showed no effect on cognitive or functional decline (16). Few trials have tested the effect of nutritional supplementation on the risk of cognitive decline in non-demented individuals. One example is the PREADVISE trial, which investigated the effect of anti-oxidants (daily doses of 400 IU vitamin E/ or placebo and 200μg selenium/or placebo) in decreasing the risk of AD among men enrolled in an even larger prostate cancer prevention study (19). Ginkgo biloba extract was also recently investigated as a preventive treatment for AD (20). Despite failing to meet the primary outcome of a reduction in the number of subjects converting to AD, some possible protective effects were observed. These subtle benefits must be confirmed in the population subgroup that took ginkgo biloba extract for at least 4 years (20). Additional studies have further investigated the effectiveness of nutrients, including omega 3 fatty acids, DHA, vitamin E, vitamin C, and coenzyme Q, using more specific neuropsychologic measures and CSF biomarkers as outcomes,

with little success (21-23). Two trials that have shown apparent benefits tested an oral ketogenic compound, AC-1202, in subjects with probable AD (24) and a medical food called Souvenaid® in subjects with mild AD (25). Souvenaid contains a specific nutrient combination patented under the name Fortasyn™ Connect, which is designed to stimulate synapse formation.

The possibility that nutritional intervention may protect against cognitive decline is an inviting prospect and data supporting a potential effect of dietary patterns are regularly published. However, long-term, large-scale randomized trials are still sparse.

#### **European Food Safety Authority (EFSA) guidelines for claims on cognitive function**

The European Food Safety Authority's Panel on Dietetic Products, Nutrition, and Allergies (NDA) issued a guidance in 2012 regarding scientific requirements to support health claims related to nervous system function for foods or food constituents such as vitamins (26).

The guidance addresses two key issues related to the substantiation of health claims: First, that health claims should only be permitted when the food or food constituent is shown to have a beneficial physiologic effect, and second, that the studies must have been well designed and executed and carried out in an appropriate study population; and that outcome measures utilize established and validated diagnostic tools, including measures of neural activity as supportive evidence of a neuropsychological benefit. A beneficial physiologic effect in the nervous system is defined as maintenance or improvement of a psychological, perceptual, psychomotor, or physiologic regulatory function; or a reduction in a disease risk factor.

With respect to the study population, the guidelines supported studies in well characterized subjects with mild cognitive decline, with extrapolation to more cognitively impaired patients considered on a case-by-case basis.

#### **What is recommended in order to obtain nutrition claims?**

The role of public agencies is to formulate guidelines to support the implementation of public health policies in the apparently healthy population. For example, the EFSA was established to develop procedures and guidelines related to food safety, and has also issued guidances related to nutrition and health claims of foods. Related to the work of the Task Force, these regulations provide definitions of nutrition references, based on nutritional requirements in order to evaluate the relationship of food consumption to age-related metabolic modifications and the nutrition of elderly people in frailty or pathological contexts (see Text box).





## JNHA: CLINICAL TRIALS AND AGING

### EFSA expectations regarding food/nutritional claims

**Characterization of the food** (this word encompasses any situation: a food, a part of a food, an ingredient, an extract, a purified natural or synthetic molecule); this characterization should be done in relation to the claim, not in an absolute way: thus it may be enough to have standardized the food for something which is considered as the active part for the claimed effect, taking into account as appropriate the content of other elements for which approved claims exist. This characterization is needed in order to check that any provided study for substantiation can actually apply to the proposed food. In case of positive outcome for the claim substantiation, this characterization will also be important for defining the conditions of use of the claim and, ultimately, will allow the possibility of control for control authorities. The applicant can choose to apply for a product-specific claim, the product being characterized by e.g. a fixed combination of nutrients and/or a specific manufacturing process: the claim substantiation should be based on studies performed with this specific product; studies performed with individual nutrients or other foods claimed to be similar can only be used as supportive evidence.

**Characterization of the target population** for the claim, leading to the issue of the possible difference between the target population and the study population. Given the constant interdiction of medicinal or therapeutic claims for foods (including dietary supplements), the target population should be an apparently healthy population, even if this population is at increased risk of a specific disease or affected by functional impairment. From the example of cholesterol-lowering food due to phytosterol content, it clearly appears that it is a matter of wording at the basis of the classification: food containing phytosterol targets people who want to maintain or reduce their blood cholesterol and do not explicitly target people with hypercholesterolemia (requiring a clinical diagnosis).

At the preliminary approach, the absence of interference (at the mechanistic level) between the drug and the food allows the inclusion of subjects using drugs in the study group. However, it would be safe to balance the groups on this aspect in order to avoid/limit any bias or uncertainty from this possible confounding factor. In any case, there is a continuum between healthy people and overtly diseased people and placing the boundary may always be questioned.

A third issue will have to be considered in the future, and at present can only be mentioned: in order to support a claim, the food should comply with a nutrient profile, according to article 4 of the claim regulation. Such point is aimed at avoiding that a food with a high content of potentially deleterious nutrients (e.g. fat, saturated fat, sugars, trans fatty acid, salt) may be promoted by simply adding 15 % of the RDA of specific vitamins or minerals.

The regulation does not contain the possibility of exemptions for health claims and risk reduction claims. Since, to date, nutrient profiles are not yet defined, this aspect leaves some uncertainty when considering multi-nutrient foods.

### Design of nutritional intervention trials targeting cognitive decline

Nutritional intervention trials that target cognitive decline are complicated by the multiple and poorly understood

pathways through which nutrition affects cognition, the multiple domains of cognition that may be affected, and individual differences in the ability to cope with neuropathology and the influence of cognitive reserve on coping. Given the heterogeneous manifestations of cognitive decline and the wide spectrum of underlying pathophysiological mechanisms, the Task Force recommended consideration of alternative and adapted designs (e.g., multidomain interventions) (27). The Task Force also identified other design considerations related to the target population and sample size, length of the trial, and selection of endpoints/outcome measures, including biomarkers:

### Target population

The EFSA guidelines supported studies in well characterized subjects with mild cognitive decline, indicating that extrapolation of the results to a larger target group may be considered on a case-by-case basis. A number of issues were identified related to the selection of the study population in order to facilitate extrapolation. In selecting a target population, the study team must take into account the intervention to be tested, the study design, and the study outcome. Several target populations may be proposed, each with specific advantages and limitations:

- The recruitment of pre-frail and frail older persons (defined according to the phenotype proposed by Fried and colleagues in the Cardiovascular Health Study (28)) with cognitive impairment (e.g., CDR equal to 0.5) may represent an interesting population since frail elders are at increased risk of having both nutritional deficiencies and dementia. In fact, the malnutrition component included in the frailty phenotype (i.e., weight loss) may enhance the possibility of implementing a nutritional intervention.
- Individuals with Mild Cognitive Impairment (MCI) may be an interesting target population, although it might be difficult to recruit these people because an evaluation in a memory center is usually needed
- PET amyloid positive individuals represent approximately 20 to 30% of older adults aged over 70 years. As they are thought to be at high risk of developing AD, they could represent a good target population although PET imaging would add substantial cost to the study..
- Other biomarkers may also be used to select appropriate study subjects.
- APOEε4 is an important risk factor for AD, and older adults who are carriers of this allele may represent a good target population for nutritional studies. Even if not used as an inclusion criteria, the presence of an APOE4 allele could be a confounding factor that needs to be taken into account in balancing study groups.
- Other populations at high risk of cognitive decline may also represent appropriate subjects, for example those with a family history of AD.





## A STATEMENT FROM THE INTERNATIONAL ACADEMY ON NUTRITION AND AGING TASK FORCE

### Sample size

Sample size calculations must be conducted for the primary outcome of the trial in order to guarantee its optimal design. Large sample sizes are likely to be needed given the heterogeneity of the decline observed across older persons

### Length of the trial

Symptomatic trials must be between 6 and 12 months in duration in order to be able to observe a decline in the placebo group. Disease modifying trials must be at least 18 months to really be able to have an effect on the disease course. (29-33). Preventive trials may require 3 to 5 years of follow-up. Although long-term randomized controlled trials (RCTs) are the ideal approach, in many cases the barriers to implementing such studies may make them unrealistic. For this reason, RCTs might aim to identify individuals at high risk of cognitive decline to make trials more efficient and economical.

Other issues to consider in planning the length of a trial include:

- The intensity, duration, and timing of the exposure, should be taken into account. Exposures may be more influential and interventions more effective during specific times and in the presence of specific conditions.
- Given the usual long subclinical, prodromal period of neurodegenerative diseases, trials need to consider extended periods of follow-up.

### Endpoints/Outcomes

The choice of outcome measures depends on the expected effects of the intervention. Since multidomain interventions may be necessary, multiple outcome measures may also be needed. The choice of outcome should also be adapted to the population under study. Studies should test the hypothesized effects of a nutritional intervention on appropriate outcome measures (i.e. cognition) by using validated, reliable and accurate psychometric tests, as well as markers of specific pathways.

Some domains (such as memory) may be considered as more “clinically relevant”, and as such, particularly important. Subjective memory complaint may represent a key feature for preventive trials on cognitive decline because associated with an increased risk for dementia. Moreover, this symptom may be easily detected by healthcare professionals (facilitating the potential participants recruitment), and has already been used in large trials. A good test of episodic memory is the Free and Cued Selective Reminding Test (FCSRT), which has shown to be predictive of memory changes in AD (34). Batteries of tests covering multiple cognitive domains have been developed and validated over the years (e.g., the Neuropsychological Test Battery (29) or the Clinician Dementia Rating scale (30).

Biomarkers (both CSF and imaging) may also be used as

secondary outcome measures, and may be measured only in a subgroup of the total population (31-33, 35, 36). They may be especially useful when anticipating a disease modifying effect or in preventive trials.

The modification of a risk factor for a disease, rather than the direct action on the disease itself may also be the subject of a claim. In the absence of a well-established risk factor for dementia or cognitive decline (such as the high level of LDL-cholesterol or blood pressure which are well established for cardiovascular disease), there should be a demonstration of both the reduction of the risk factor and of the disease itself.

Other important considerations when selecting outcome measures include:

- tests (especially those used in prevention trials) should be sufficiently sensitive to changes.
- For the EFSA, it is the responsibility of the applicant to demonstrate that the test chosen has been validated for the purpose (i.e. cognitive decline) in the specific population.
- In the statistical treatment of the results, the consideration of multiple outcomes should be done using appropriate statistical corrections.
- Other factors that may need to be assessed as covariates include nutritional status, physical exercise and cognitive activity.

### Conclusion

Nutrition is a domain that should be more fully explored as a determinant of cognitive impairment in the older persons. Moreover, links between nutrition and physical and cognitive frailty make this an area of particular interest for nutrition intervention (37-39).

The efficacy of nutritional interventions on cognition should be tested using recommendations that mirror those already established for the design of pharmacological trials. For example, the selection of a target population, study design, and the study outcome for appropriate the tested intervention is very important. With regard to the study design, large sample sizes will most likely be needed. For symptomatic treatments, trials of between 6 and 12 months in duration will be required in order to detect a decline in the placebo group, while preventive trials may require 3 to 5 years of follow-up.

The EFSA reports that of 2,927 consolidated health claims for different ingredients examined, only 241 passed muster. This high rejection rate in an industry that has lobbied against legislation requiring stricter approval standards and costly quality control (40) prompted the members of this Task Force to propose ambitious and robust trials aimed at obtaining similar success to those obtained in the past for cardiovascular diseases and osteoporosis.

*Acknowledgements to:* Esther Kalonji, (Agence Nationale de Sécurité Sanitaire de l'Alimentation, de l'Environnement et du Travail, Maisons-Alfort, France (ANSES) and A. Martin (NDA scientific panel in EFSA) for having presented and explained EFSA processes and guidance documents; and to Lisa J. Bain for editorial assistance.





## JNHA: CLINICAL TRIALS AND AGING

**Task Force members:** Sandrine Andrieu, France; Cécile Bonhomme, France; Jean Paul Caubère, France; Matteo Cesari, France; Nicola Coley, France; Monique Ferry, France; Julien Gautry, France; Ines Garcia Sanchez, Belgium; Laurence Hugonot, France; Lucilla Mansuy, France; John Morley, USA; Pierre-Jean Ousset, France; Marco Pahor, USA; Jérémie Pariente, France; Patrick Ritz, France; Leocadio Rodriguez Manas, Spain; Arendi Rosseel, The Netherlands; Antoni Salva, Spain; John Sijben, The Netherlands; Alan J Sinclair, United Kingdom; Bruno Vellas, France; Rico Wieggers, The Netherlands; Pascale Ythier-Moury, France; Mohammed Zaim, France; Jean Zetlaoui, Switzerland

### References

- World Health Organization. Diet, Nutrition and the Prevention of Chronic Diseases: report of a joint WHO/FAO expert consultation. Geneva, Switzerland; 2003 WHO Technical Reports Series n° 916
- Barberger-Gateau P, Raffaitin C, Letenneur L, Berr C, Tzourio C, Dartigues JF, et al. Dietary patterns and risk of dementia: the Three-City cohort study. *Neurology*. 2007; 69(20):1921-30.
- Morris MS, Selhub J, Jacques PF. Vitamin B-12 and folate status in relation to decline in scores on the mini-mental state examination in the Framingham heart study. *J Am Geriatr Soc*. 2012; 60(8):1457-64.
- Shatenstein B, Ferland G, Belleville S, Gray-Donald K, Kergoat MJ, Morais J, et al. Diet quality and cognition among older adults from the NuAge study. *Exp Gerontol*. 2012; 47(5):353-60.
- Kesse-Guyot E, Amieva H, Castetbon K, Henegar A, Ferry M, Jeandel C, et al. Adherence to nutritional recommendations and subsequent cognitive performance: findings from the prospective Supplementation with Antioxidant Vitamins and Minerals 2 (SU.VI.MAX 2) study. *Am J Clin Nutr*. 2011; 93(1):200-10.
- McMahon JA, Green TJ, Skeaff CM, Knight RG, Mann JI, Williams SM. A controlled trial of homocysteine lowering and cognitive performance. *N Engl J Med*. 2006; 354(26):2764-72.
- Valls-Pedret C, Lamuela-Raventos RM, Medina-Rejon A, Quintana M, Corella D, Pinto X, et al. Polyphenol-rich foods in the Mediterranean diet are associated with better cognitive function in elderly subjects at high cardiovascular risk. *J Alzheimers Dis*. 2012; 29(4):773-82.
- Luchsinger JA, Mayeux R. Dietary factors and Alzheimer's disease. *Lancet Neurol*. 2004; 3(10):579-87.
- Morris MC, Evans DA, Tangney CC, Bienias JL, Wilson RS. Fish consumption and cognitive decline with age in a large community study. *Arch Neurol*. 2005; 62(12):1849-53.
- Gillette Guyonnet S, Abellan Van Kan G, Andrieu S, Barberger Gateau P, Berr C, Bonnefoy M, et al. IANA task force on nutrition and cognitive decline with aging. *J Nutr Health Aging*. 2007; 11(2):132-52.
- Calvaresi E, Bryan J. B vitamins, cognition, and aging: a review. *J Gerontol B, Psychol Sci Social Sci*. 2001; 56(6):327-39.
- Berr C, Balansard B, Arnaud J, Roussel AM, Alperovitch A. Cognitive decline is associated with systemic oxidative stress: the EVA study. *Etude du Vieillissement Arteriel. J Am Geriatr Soc*. 2000; 48(10):1285-91.
- Tucker KL, Qiao N, Scott T, Rosenberg I, Spiro A, 3rd. High homocysteine and low B vitamins predict cognitive decline in aging men: the Veterans Affairs Normative Aging Study. *Am J Clin Nutr*. 2005; 82(3):627-35.
- Kado DM, Karlamangla AS, Huang MH, Troen A, Rowe JW, Selhub J, et al. Homocysteine versus the vitamins folate, B6, and B12 as predictors of cognitive function and decline in older high-functioning adults: MacArthur Studies of Successful Aging. *Am J Med*. 2005; 118(2):161-7.
- Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. *JAMA*. 2008; 300(15):1774-83.
- Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. *JAMA*. 2010; 304(17):1903-11.
- Daviglus ML, Bell CC, Berrettini W, Bowen PE, Connolly ES, Jr., Cox NJ, et al. National Institutes of Health State-of-the-Science Conference statement: preventing Alzheimer disease and cognitive decline. *Ann Intern Med*. 2010; 153(3):176-81.
- Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet*. 2002; 360(9326):23-33.
- Kryscio RJ, Abner EL, Schmitt FA, Goodman PJ, Mendiondo M, Caban-Holt A, et al. A randomized controlled Alzheimer's disease prevention trial's evolution into an exposure trial: the PREADViSE Trial. *J Nutr Health Aging*. 2013; 17(1):72-5.
- Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B, et al. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. *Lancet Neurol*. 2012; 11(10):851-9.
- Dangour AD, Allen E, Elbourne D, Fasey N, Fletcher AE, Hardy P, et al. Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial. *Am J Clin Nutr*. 2010; 91(6):1725-32.
- Farina N, Isaac MG, Clark AR, Rusted J, Tabet N. Vitamin E for Alzheimer's dementia and mild cognitive impairment. *Cochrane Database Syst Rev*. 2012; 11:CD002854.
- Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, et al. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. *Arch Neurol*. 2012; 69(7):836-41.
- Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. *Nutr Metab (Lond)*. 2009; 6:31.
- Scheltens P, Twisk JW, Blesa R, Scarpini E, von Arnim CA, Bongers A, et al. Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. *J Alzheimers Dis*. 2012; 31(1):225-36.
- European Food Safety Authority. Guidance on the scientific requirements for health claims related to functions of the nervous system, including psychological functions. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). *Journal [serial on the Internet]*. 2012 Date; 10(7): Available from: <http://www.efsa.europa.eu/en/efsajournal/doc/2816.pdf>.
- Gillette-Guyonnet S, Andrieu S, Dantoine T, Dartigues JF, Touchon J, Vellas B, et al. Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008." The Multidomain Alzheimer Preventive Trial (MAPT): a new approach to the prevention of Alzheimer's disease. *Alzheimer's & dementia : J Alzheimers Association*. 2009; 5(2):114-21.
- Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci*. 2001; 56(3):M146-56.
- Harrison J, Minassian SL, Jenkins L, Black RS, Koller M, Grundman M. A neuropsychological test battery for use in Alzheimer disease clinical trials. *Arch Neurol*. 2007; 64(9):1323-9.
- Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. *Neurology*. 1993; 43(11):2412-4.
- Vellas B, Andrieu S, Sampaio C, Coley N, Wilcock G, European Task Force G. Endpoints for trials in Alzheimer's disease: a European task force consensus. *Lancet Neurol*. 2008; 7(5):436-50.
- Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, Dubois B, et al. Report of the task force on designing clinical trials in early (predementia) AD. *Neurology*. 2011; 76(3):280-6.
- Vellas B, Hampel H, Rouge-Bugat ME, Grundman M, Andrieu S, Abu-Shakra S, et al. Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology. *J Nutr Health Aging*. 2012; 16(4):339-45.
- Grober E, Lipton RB, Hall C, Crystal H. Memory impairment on free and cued selective reminding predicts dementia. *Neurology*. 2000; 54(4):827-32.
- Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. *Lancet Neurol*. 2007; 6(8):734-46.
- Sarazin M, Berr C, De Rotrou J, Fabrigoule C, Pasquier F, Legrain S, et al. Amnesic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study. *Neurology*. 2007; 69(19):1859-67.
- Cesari M. Frailty and aging. *J Frailty Aging*. 2012; 3:6.
- Kehayias JJ, Ribeiro SM, Skahan A, Itzkowitz L, Dallal G, Rogers G, et al. Water homeostasis, frailty and cognitive function in the nursing home. *J Nutr Health Aging*. 2012; 16(1):35-9.
- Mulero J, Zafrilla P, Martinez-Cacha A. Oxidative stress, frailty and cognitive decline. *J Nutr Health Aging*. 2011; 15(9):756-60.
- Editorial: Culture shock. Health-benefit claims for Europe's foods must at last be substantiated by science. *Nature*. 2013; 493:133-4.

